X
Adaptations and positivity are key to living in the light with LHON sight loss
https://pharmaphorum.com/disease-spotlight/adaptions-and-positivity-are-key-to-living-in-the-light-with-lhon-sight-loss/
Santhera
EU regulators reject Santhera’s Raxone for DMD
Swiss company to appeal regulators’ decision.
UK patients gain early access to Duchenne drug
Patients to get Santhera’s Raxone under EAMS scheme.
Santhera DMD drug has setback in US
Approval unlikely before 2020.
